BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23558905)

  • 1. Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.
    Lee SM; Lee WS; Shin HJ; Lee JJ; Sohn SK; Moon JH; Eom HS; Won JH; Lee KH; Lee JH; Kim DY; Yoon SS; Kim I; Jung CW; Kim SJ; Kim H; Lee JH; Ryoo HM; Lee GW; Kim SH; Mun YC; Kim MK; Joo YD;
    Ann Hematol; 2013 Aug; 92(8):1101-10. PubMed ID: 23558905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of 71 adult acute lymphoblastic leukemia].
    Yoshida M; Kurata H; Tsunoda S; Iwama A; Suzuki T; Akutsu M; Imagawa S; Tsunoda J; Furukawa Y; Komatsu N
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1827-33. PubMed ID: 8379676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
    Chiu EK; Chan LC; Liang R; Lie A; Kwong YL; Todd D; Chan TK
    Leukemia; 1994 Sep; 8(9):1469-73. PubMed ID: 8090027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen.
    Wiernik PH; Dutcher JP; Paietta E; Gucalp R; Markus S; Weinberg V; Azar C; Garl S; Benson L
    Leukemia; 1993 Aug; 7(8):1236-41. PubMed ID: 8350624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
    Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period.
    Ferrari A; Annino L; Crescenzi S; Romani C; Mandelli F
    Leukemia; 1995 Oct; 9(10):1643-7. PubMed ID: 7564503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The programmed therapy of acute lymphoblastic leukemia in adults].
    Isaev VG; Savchenko VG; Kucher RA; Abakumov EM; Parovichnikova EN
    Ter Arkh; 1992; 64(8):82-7. PubMed ID: 1440405
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
    Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
    Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia.
    Todeschini G; Meneghini V; Pizzolo G; Cassibba V; Ambrosetti A; Veneri D; Nadali G; Zanotti R; Tecchio C; Perona G
    Leukemia; 1994 Mar; 8(3):376-81. PubMed ID: 8127142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
    Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
    Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study.
    Cuttner J; Mick R; Budman DR; Mayer RJ; Lee EJ; Henderson ES; Weiss RB; Paciucci PA; Sobol R; Davey F
    Leukemia; 1991 May; 5(5):425-31. PubMed ID: 2033963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
    Hunault-Berger M; Milpied N; Bernard M; Jouet JP; Delain M; Desablens B; Sadoun A; Guilhot F; Casassus P; Ifrah N
    Leukemia; 2001 Jun; 15(6):898-902. PubMed ID: 11417474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee KH; Lee JH; Choi SJ; Lee JH; Seol M; Lee YS; Kim WK; Lee JS; Seo EJ; Jang S; Park CJ; Chi HS
    Leukemia; 2005 Sep; 19(9):1509-16. PubMed ID: 16034462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
    Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
    J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.